These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35562199)

  • 1. Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders.
    Lopez-Cuina M; Meissner WG
    Rev Neurol (Paris); 2022 May; 178(5):460-471. PubMed ID: 35562199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific glycosaminoglycan chain length and sulfation patterns are required for cell uptake of tau
    Stopschinski BE; Holmes BB; Miller GM; Manon VA; Vaquer-Alicea J; Prueitt WL; Hsieh-Wilson LC; Diamond MI
    J Biol Chem; 2018 Jul; 293(27):10826-10840. PubMed ID: 29752409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overlaps and divergences between tauopathies and synucleinopathies: a duet of neurodegeneration.
    Li W; Li JY
    Transl Neurodegener; 2024 Mar; 13(1):16. PubMed ID: 38528629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-synuclein and tau: teammates in neurodegeneration?
    Moussaud S; Jones DR; Moussaud-Lamodière EL; Delenclos M; Ross OA; McLean PJ
    Mol Neurodegener; 2014 Oct; 9():43. PubMed ID: 25352339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration.
    Goedert M; Masuda-Suzukake M; Falcon B
    Brain; 2017 Feb; 140(2):266-278. PubMed ID: 27658420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of α-synuclein and Tau: A molecular conspiracy in neurodegeneration?
    Yan X; Uronen RL; Huttunen HJ
    Semin Cell Dev Biol; 2020 Mar; 99():55-64. PubMed ID: 29738880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-to-Cell Transmission of Tau and α-Synuclein.
    Uemura N; Uemura MT; Luk KC; Lee VM; Trojanowski JQ
    Trends Mol Med; 2020 Oct; 26(10):936-952. PubMed ID: 32371172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neuropathology of tauopathies and synucleinopathies, and neuroanatomy of sleep disorders: meeting the challenge].
    Hauw JJ; Hausser-Hauw C; Duyckaerts C
    Rev Neurol (Paris); 2003 Nov; 159(11 Suppl):6S59-70. PubMed ID: 14646802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of Tau and α-Synuclein Pathology in the Visual System.
    Rahimi J; Milenkovic I; Kovacs GG
    J Parkinsons Dis; 2015; 5(2):333-40. PubMed ID: 25737267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies.
    Zhang X; Wang J; Zhang Z; Ye K
    Transl Neurodegener; 2024 Aug; 13(1):40. PubMed ID: 39107835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases.
    Lee VM; Giasson BI; Trojanowski JQ
    Trends Neurosci; 2004 Mar; 27(3):129-34. PubMed ID: 15036877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein.
    Quint WH; Matečko-Burmann I; Schilcher I; Löffler T; Schöll M; Burmann BM; Vogels T
    J Alzheimers Dis; 2021; 80(2):813-829. PubMed ID: 33579845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration.
    Yeboah F; Kim TE; Bill A; Dettmer U
    Neurobiol Dis; 2019 Dec; 132():104543. PubMed ID: 31351173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.
    Valera E; Spencer B; Masliah E
    Neurotherapeutics; 2016 Jan; 13(1):179-89. PubMed ID: 26494242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation and oligomerization of α-synuclein associated with GSK-3β activation in the rTg4510 mouse model of tauopathy.
    Takaichi Y; Chambers JK; Inoue H; Ano Y; Takashima A; Nakayama H; Uchida K
    Acta Neuropathol Commun; 2020 Jun; 8(1):86. PubMed ID: 32560668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-synuclein abnormalities trigger focal tau pathology, spreading to various brain areas in Parkinson disease.
    Hadi F; Akrami H; Totonchi M; Barzegar A; Nabavi SM; Shahpasand K
    J Neurochem; 2021 May; 157(3):727-751. PubMed ID: 33264426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct sets of lysosomal genes define synucleinopathy and tauopathy.
    Oh KW; Kim DK; Hsu AL; Lee SJ
    BMB Rep; 2023 Dec; 56(12):657-662. PubMed ID: 37817435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein.
    Martinez-Valbuena I; Valenti-Azcarate R; Amat-Villegas I; Marcilla I; Marti-Andres G; Caballero MC; Riverol M; Tuñon MT; Fraser PE; Luquin MR
    Acta Neuropathol Commun; 2021 Apr; 9(1):64. PubMed ID: 33832546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between α-synuclein and other proteins in neurodegenerative disorders.
    Jellinger KA
    ScientificWorldJournal; 2011; 11():1893-907. PubMed ID: 22125446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in α-synuclein, TDP-43 and tau prolong protein half-life through diminished degradation by lysosomal proteases.
    Sampognaro PJ; Arya S; Knudsen GM; Gunderson EL; Sandoval-Perez A; Hodul M; Bowles K; Craik CS; Jacobson MP; Kao AW
    Mol Neurodegener; 2023 May; 18(1):29. PubMed ID: 37131250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.